ClinicalTrials.gg
CompletedNCT02132299Updated Apr 27, 2016

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

A Phase 1 interventional study of PfSPZ Vaccine and Normal Saline (Placebo) in Malaria and Plasmodium Falciparum Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Tanzania. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-27.

Primary conditionMalaria, FalciparumRegistry: MalariaReclassifiedWhy we changed it
Registry
Malaria — the first condition term the registry derived for this study.
ClinicalTrials.gg
Malaria, Falciparum
Why
  1. The study's listed conditions name Malaria, Falciparum, a narrower term within Malaria.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing PfSPZ Challenge in Malaria, Falciparum — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria, Falciparum.

Enrollment
Largest of 12
67 · median 31
Started
2014
with 2 others
Phase 1
11 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
10 of 12
Sanaria Inc.

Among the 12 studies testing PfSPZ Challenge in Malaria, Falciparum, this one has the largest enrollment, is one of 3 that started in 2014, is one of 11 in phase 1, and was the 7th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

1 of the 12 studies testing PfSPZ Challenge in Malaria, Falciparum is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About PfSPZ Challenge

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing PfSPZ Challenge in Malaria, Falciparum, or all of them as a file.
02

Study summary

This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P. falciparum infection after inoculation of aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) Plasmodium falciparum sporozoites (PfSPZ Vaccine) administered intravenously (IV).

Read the detailed description

This is a single center, Phase 1, dose escalating, randomized, double blind, controlled trial. Seventy-three healthy male volunteers, aged 18 to 35 years will be recruited. The study will have 5 study groups that will include 49 volunteers who will be intravenously injected with PfSPZ Vaccine, 8 control volunteers who will receive normal saline and 16 additional control volunteers who will be recruited at the time of controlled human malaria infection (CHMI) at 3 and 24 weeks. The control volunteers will help better assess the occurrence of AEs compared to background disease patterns that occur in this tropical area, and the performance of the vaccine.

03

Conditions studied

  • Malaria
  • Plasmodium Falciparum Malaria

Browse trials for

Keywords

  • Malaria
  • Plasmodium falciparum malaria
  • PfSPZ Vaccine
  • PfSPZ Challenge
  • Controlled human malaria infection (CHMI)
04

In context

Malaria, Falciparum Reclassified

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

This study's enrollment of 67 is below the median of 126 across 376 interventional studies indexed under Malaria, Falciparum.

Browse Malaria, Falciparum studies →

Lead sponsor

Sanaria Inc. is the lead sponsor of 29 studies on the registry; 4 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Compared within Malaria, Falciparum, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Malaria. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male aged between 18 - 35 years.
  • Good health status based on history and clinical examination.
  • Long term or permanent resident in or near Dar-es-Salaam.
  • Able and willing to complete the study visit schedule over the one year follow up period, including the hospitalizations required for protocol compliance.
  • Able and willing to complete the process conducted in English.
  • Demonstrate understanding of the study and procedures by answering 20 questions from the Protocol \& Study Procedures Understanding Checklist correctly with a maximum of two attempts.
  • Agrees to inform study doctor of medical conditions and for participation in the study.
  • Agrees to provide contact information to the study team for a household member who will serve as an emergency contact during trial participation.
  • Willing to be attended by a study doctor and take medications, which may be prescribed by a study doctor, during study participation.
  • Reachable (24/7) by mobile phone during the whole study period.
  • Agrees not to participate in another study during the study period.
  • Agrees not to donate blood during the study period.
  • Willing to undergo , and testing.
  • Willing to undergo controlled human malaria infection (CHMI).

Exclusion criteria

Exclusion Criteria:

  • History of malaria in the past 5 years.
  • Positive for malaria by thick blood smear at screening.
  • Plans to travel outside the Dar-es-Salaam or Coast Region in first 12 months of the study.
  • Previous receipt of an malaria vaccine.
  • Antibodies to parasites or selected parasite protein(s) above acceptable cut off established for the site
  • History of arrhythmias or prolonged -interval or other cardiac disease or abnormalities in (ECG) at screening.
  • History or indication of a history of drug or alcohol abuse interfering with normal social function.
  • Use of chronic drugs, antibiotics, or other immune modifying drugs within three months of study enrollment (inhaled and topical are allowed).
  • Ongoing condition that could interfere with the interpretation of the study results or compromise the health of the volunteer.
  • History of diabetes mellitus or cancer.
  • (BMI) below 18 or above 30 kg/m2.
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes.
  • Positive , virus or virus tests.
  • Participation in any other clinical study within 30 days prior to study enrollment.
  • Known , allergy, or other to Coartem® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.
  • Heterozygous or homozygous for sickle cell or homozygous for alpha thalassemia.
  • Glucose-6-phosphate dehydrogenase deficiency
  • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of suicide plan or attempt.
  • Any medical, psychiatric, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's ability to give , increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
  • History of 3 or more other immunizations within the six months before administration of the first dose of vaccine.
  • Clinically active tuberculosis
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Group 1

    Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10\^4, 1.35x10\^5, and 2.7x10\^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.

    Biological: PfSPZ Vaccine

  • Experimental
    Group 2(A)

    Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10\^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge

  • Placebo comparator
    Group 2(B)

    Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).

    Biological: Normal Saline (Placebo) · Biological: PfSPZ Challenge

  • Experimental
    Group 3(A)

    Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10\^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge

  • Placebo comparator
    Group 3(B)

    Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54).

    Biological: Normal Saline (Placebo) · Biological: PfSPZ Challenge

  • Experimental
    Group 4

    The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10\^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10\^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge

  • Placebo comparator
    Group 5

    The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.

    Biological: PfSPZ Challenge

Interventions

  • BiologicalPfSPZ Vaccine

    Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

  • BiologicalNormal Saline (Placebo)
  • BiologicalPfSPZ Challenge

    Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

07

What researchers measure

Primary outcomes

  1. Safety and tolerability endpoints

    * Solicited local (IV site) and systemic AEs (AEs) observed in the 7 days after each vaccination and each CHMI. * Unsolicited AEs observed after the first vaccination until day 28 after the last vaccination for volunteers who do not undergo CHMI#1 (e.g. Group 1, those who do not complete the CHMI portion in Groups 2 and 3, and volunteers in Group 4). * Unsolicited AEs observed after the first vaccination until day 28 after the CHMI#1 for volunteers who undergo CHMI#1 3 weeks after the last vaccination (e.g. Groups 2 and 3). * Unsolicited AEs observed from day CHMI#2 (which occurs 24 weeks after the last vaccination) until day 28 after CHMI#2 (e.g. Groups 2-5).

    Time frame: Vaccination to CHMI (or 28 days after last vaccination); CHMI to 28 days after CHMI

  2. Protective Efficacy after CHMI with PfSPZ Challenge (NF54) - CHMI Endpoints

    Number of volunteers that remain parasite negative in each group through day 28 of follow up after CHMI with PfSPZ Challenge (NF54) IV inoculation. Three weeks after their last immunization, volunteers in Groups 2 and 3 will under go their first CHMI with 3.2 x 10\^3 PfSPZ Challenge (NF54) administered IV. Twenty-four weeks after the last immunization, volunteers from Groups 2 and 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10\^3 PfSPZ Challenge (NF54). Volunteers in Groups 4 and 5 will only participate in the second CHMI assessment. After CHMI, volunteers will be followed for evidence of infection with blood smears for 28 days.

    Time frame: CHMI to 28 days after CHMI

Secondary outcomes

  1. Immune Responses after PfSPZ Vaccine

    Cellular and humoral immune responses will be assessed in the vaccinated volunteers and controls (including central and effector memory responses and breadth and specificity of malaria antibodies).

    Time frame: 16 months

  2. Protective effect of the high dose PfSPZ Vaccine regimen

    Number of volunteers negative in Group 3 and Group 4 compared to Group 2 through day 28 of follow up after homologous PfSPZ Challenge (NF54) IV inoculation.

    Time frame: CHMI to day 28 after CHMI

Other outcomes

  1. Exploratory Endpoints - Immune Responses

    Malaria specific immune responses in Groups 2, 3 and 4 as compared to the malaria naïve volunteers immunized at Vaccine Research Center of the NIH (protocol VRC 312) who received 1.35x10\^5 PfSPZ/dose.

    Time frame: 16 months

08

Study locations

1 site
  • Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74
    Bagamoyo, Tanzania
09

References and documents

Publications

  • Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, Rutishauser T, Rothen J, Tumbo A, Mkindi C, Mpina M, Mtoro AT, Ishizuka AS, Kassim KR, Milando FA, Qassim M, Juma OA, Mwakasungula S, Simon B, James ER, Abebe Y, Kc N, Chakravarty S, Saverino E, Bakari BM, Billingsley PF, Seder RA, Daubenberger C, Sim BKL, Richie TL, Tanner M, Abdulla S, Hoffman SL. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018 Aug;99(2):338-349. doi: 10.4269/ajtmh.17-1014. Epub 2018 Jun 21. PubMed 29943719 ↗
  • Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, Flannery EL, Nguyen T, Fishbaugher M, Steel RWJ, Betz W, Carmago N, Mikolajczak S, Kappe SHI, Hoffman SL, Sack BK, Daubenberger C. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies. J Infect Dis. 2018 Apr 23;217(10):1569-1578. doi: 10.1093/infdis/jiy080. PubMed 29438525 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 7, 2014
Start
Apr 2014
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02132299
Lead sponsor
Sanaria Inc.
Collaborators
Ifakara Health Institute, Swiss Tropical & Public Health Institute, Tanzania Commission for Science and Technology
Responsible party
Sponsor
First posted
May 7, 2014
Start date
Apr 2014
Primary completion
Jul 2015
Completion
Aug 2015
Last update
Apr 27, 2016

Study contacts

Salim Abdulla, MD, PhD
principal investigator · Ifakara Health Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PfSPZ Challenge

Start the discussion